0 (0%)		09-27 14:45
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	2.76	1-year :	3.23
Resists	First :	2.36	Second :	2.76
Pivot price	2.32
Supports	First :	1.95	Second :	1.7
MAs	MA(5) :	2.34	MA(20) :	2.23
	MA(100) :	2.65	MA(250) :	7.21
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	96.2	D(3) :	96.2
RSI	RSI(14): 63.4
52-week	High :	18.94	Low :	0.11

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BBI ] has closed below upper band by 43.3%. Bollinger Bands are 73.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 85 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.37 - 2.38	2.38 - 2.39
Low:	2.18 - 2.2	2.2 - 2.21
Close:	2.33 - 2.35	2.35 - 2.37

Tue, 27 May 2025
Boundless Bio lays off 33% of staff as lead program stumbles - Fierce Biotech

Sun, 25 May 2025
BBI Autosport leads triple Porsche race effort at 2021 Pikes International Hill Climb - PorscheSport

Sun, 18 May 2025
2025 BBI ALL-NBA Teams - Basketball Index

Sat, 17 May 2025
A phase 1b randomised clinical trial evaluating BBI-001, a non-absorbed oral therapeutic for the treatment of iron overload | Scientific Reports - Nature

Wed, 14 May 2025
Tauil & Chequer Advogados acted as counsel for BTG Pactual, Bradesco BBI, Santander, Citi and Safra banks on the BRL 2.4 billion public offering of debentures issued by V.tal - Mayer Brown

Thu, 08 May 2025
A long-term mixed eosinophilic and neutrophilic chronic rhinosinusitis C57BL/6 mouse model with neuroinflammation, olfactory dysfunction and anxiety-like behaviors - ScienceDirect.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	0 (M)
Shares Float	115 (M)
Held by Insiders	2.48e+006 (%)
Held by Institutions	1.3 (%)
Shares Short	108 (K)
Shares Short P.Month	0 (K)

EPS	-4.062e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-8 %
Return on Assets (ttm)	486.2 %
Return on Equity (ttm)	-85.2 %
Qtrly Rev. Growth	479000 %
Gross Profit (p.s.)	1076.09
Sales Per Share	-430.47
EBITDA (p.s.)	-6.7878e+007
Qtrly Earnings Growth	-0.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-40 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	4.37

Dividend	0
Forward Dividend	181260
Dividend Yield	0%
Dividend Pay Date	2019-09-02
Ex-Dividend Date	Invalid DateTime.